Loading…
Loading…
ASAS criteria, MRI sacroiliitis grading, and TNF/IL-17 biologic stratification
Ankylosing spondylitis (AS) is a chronic inflammatory axial spondyloarthropathy characterised by sacroiliitis, enthesitis, and progressive spinal fusion that leads to significant functional impairment if untreated. At Dr. Shree Narayan's clinic, early diagnosis is pursued using the ASAS classification criteria (inflammatory back pain plus MRI sacroiliitis or HLA-B27 plus two additional spondyloarthropathy features), and treatment follows a T2T approach using BASDAI and ASDAS scores to guide escalation from NSAIDs to biologic DMARDs. Anti-TNF agents remain first-line biologics, with IL-17 inhibitors (secukinumab, ixekizumab) offering an alternative for patients with inadequate response or contraindications to anti-TNF therapy. Peripheral manifestations including enthesitis, dactylitis, and arthritis are addressed concurrently.
Kathmandu Neurology Clinic & Cognitive Center
Authored and reviewed by Dr. Shree Narayan Yadav (MBBS (KU), MD-Internal Medicine (NAMS), MSc Clinical Rheumatology (USW, UK), NMC 14227). Evidence-based, no fabricated outcomes.
Ankylosing spondylitis (AS) is a chronic inflammatory axial spondyloarthropathy characterised by sacroiliitis, enthesitis, and progressive spinal fusion that leads to significant functional impairment if untreated. At Dr. Shree Narayan's clinic, early diagnosis is pursued using the ASAS classification criteria (inflammatory back pain plus MRI sacroiliitis or HLA-B27 plus two additional spondyloarthropathy features), and treatment follows a T2T approach using BASDAI and ASDAS scores to guide escalation from NSAIDs to biologic DMARDs. Anti-TNF agents remain first-line biologics, with IL-17 inhibitors (secukinumab, ixekizumab) offering an alternative for patients with inadequate response or contraindications to anti-TNF therapy. Peripheral manifestations including enthesitis, dactylitis, and arthritis are addressed concurrently.
Reviewed by Dr. Shree Narayan Yadav, MBBS, MD, MSc — Consultant Physician & Joint and Autoimmune Disease Specialist (NMC 14227), Kathmandu Neurology Clinic. For evaluation, book an appointment.
The hallmark of AS is chronic inflammatory back pain with insidious onset before age 40,改善 with exercise and morning stiffness lasting more than 30 minutes. The ASAS 2009 classification criteria define axial spondyloarthropathy as inflammatory back pain (>=3 months) plus either sacroiliitis on imaging (MRI or X-ray) or HLA-B27 positivity with two or more spondyloarthropathy features. Delayed diagnosis averages 5 to 7 years from symptom onset, during which structural damage accumulates. MRI of the sacroiliac joints with STIR sequences detects active sacroiliitis (bone marrow oedema) before radiographic changes become apparent.
Anti-TNF agents (adalimumab, etanercept, infliximab, golimumab, certolizumab) are first-line biologics for AS patients with active disease despite optimal NSAID therapy (BASDAI >=4 or ASDAS >=2.1). Response is assessed at 12 weeks using ASDAS (inactive disease <1.3, major improvement >=2.0). IL-17A inhibitors (secukinumab, ixekizumab) are recommended as second-line biologics for anti-TNF failures or contraindication, supported by the MEASURE and COAST trials demonstrating significant improvement in ASAS20/40 response rates and spinal inflammation on MRI.
Guidelines referenced:
Rudwaleit M et al. The Assessment of SpondyloArthritis international Society (ASAS) classification criteria. Ann Rheum Dis 2009Ward MM et al. 2019 ACR/ASAS treatment guidelines for axial spondyloarthritis. Arthritis RheumatolBaraliakos X et al. Secukinumab in ankylosing spondylitis: 5-year results from the MEASURE studies. Lancet RheumatolContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.